CN111437301A - 槐花蛹虫草制剂 - Google Patents
槐花蛹虫草制剂 Download PDFInfo
- Publication number
- CN111437301A CN111437301A CN202010404779.9A CN202010404779A CN111437301A CN 111437301 A CN111437301 A CN 111437301A CN 202010404779 A CN202010404779 A CN 202010404779A CN 111437301 A CN111437301 A CN 111437301A
- Authority
- CN
- China
- Prior art keywords
- cordyceps militaris
- sophora flower
- preparation
- blood
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 241000219784 Sophora Species 0.000 title claims abstract description 15
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 10
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 10
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 10
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 7
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 7
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 abstract description 26
- 206010011224 Cough Diseases 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract description 11
- 206010035664 Pneumonia Diseases 0.000 abstract description 8
- 208000006673 asthma Diseases 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 8
- 201000006306 Cor pulmonale Diseases 0.000 abstract description 7
- 206010016654 Fibrosis Diseases 0.000 abstract description 7
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract description 7
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 7
- 208000002672 hepatitis B Diseases 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 206010003445 Ascites Diseases 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 abstract description 6
- 208000036319 cervical spondylosis Diseases 0.000 abstract description 6
- 230000007882 cirrhosis Effects 0.000 abstract description 6
- 230000002440 hepatic effect Effects 0.000 abstract description 6
- 230000002458 infectious effect Effects 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 208000005801 spondylosis Diseases 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 238000001816 cooling Methods 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract description 3
- 241000222336 Ganoderma Species 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000000552 rheumatic effect Effects 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 240000001579 Cirsium arvense Species 0.000 abstract 1
- 235000005918 Cirsium arvense Nutrition 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 241000229143 Hippophae Species 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 241000628997 Flos Species 0.000 description 5
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 5
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000931705 Cicada Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241001237431 Anomala Species 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 235000014290 Artemisia anomala Nutrition 0.000 description 1
- 241000123844 Artemisia anomala Species 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047097 Vascular purpura Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000006493 arterial relaxation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
槐花蛹虫草制剂是由:槐花400g‑800g、蛹虫草300g‑600g、平卧菊三七300g‑600g、沙棘300g‑600g、余甘子200g‑400g、小蓟100g‑200g制剂,具有清热解毒、保肝护肝、活血化於、凉血止血、利水、提升人体免疫力的作用,能有效的***、肝硬化、肝腹水、风湿骨痛、颈椎病、腰椎病、咳嗽、哮喘、肺心病,纯药食同源剂、无毒毒作用,制剂可加入广东刘寄奴、灵芝、白芷为辅料,可增强对重型病毒感染性肺炎及其并发症治疗的疗效。
Description
技术领域:本发明为药食同源领域,具体是槐花蛹虫草制剂。
背景技术:随着社会的快速发展,人们的工作压力也随之增大,部分人对养生、健身的认识不够,随着年龄的增大,免疫力越来越底,那些早已取于亚健康的人群、对自已的身体调理没有引起重视,日积月垒、到最后久治不愈,转发成为重大的疑难病症;如:乙肝、肝硬化、肝腹水、风湿骨痛、哮喘、肺心病,这些病症现已成上升趋势,现有治疗此类病的中西药品种繁多,但大都效果不佳、须常年用药,而且副作用大、造成多种并发症,为此人们急待有一种能有效治疗以上多种病、而且无毒副作用的药品问世,本人在行医过程中、组建中医药研究所,收集各种民间偏方与秘方进行处方重组、用于临床,对以上病症取得了重大突破,使用方剂是由:槐花、蛹虫草、平卧菊三七、沙棘、余甘子、小蓟组成,使用此方已治愈乙肝、肝硬化、肝腹水、颈椎病、腰推病、类风湿、以及病毒感染性肺炎而引发的咽炎、咳嗽、哮喘、肺心病患者上千例,有效率在90%以上,在进一步的研化过程中发现,以本方配比基础加入少量广东刘寄奴、灵芝、白芷为辅料,可提高制剂对重型病毒感染性肺炎引发的咽炎、咳嗽、哮喘、肺心病疗效,现在人类面临新型冠状感染的肺炎还没有很好疗效的制剂,本所研化的槐花蛹虫草制剂、技木成熟、可产将配方中的蛹虫草、平卧菊三七等原料进一步提取、纯化,再通过注射新冠病毒建立治疗新冠病毒感染性肺炎的小鼠试验模型,然后给与不同剂量,进行疗效评估和安全剂量评估,然后用于新冠病毒感染的肺炎人群进行有效防治,为人类作出重大更献。
发明内容:槐花蛹虫草制剂是由:槐花400g一800g、蛹虫草300g一600g、平卧菊三七300g一600g、沙棘300g一600g、余甘子200g一400g、小蓟100g一200g制成,具有清热解毒、保肝护肝、活血化於、凉血止血、利水、提升人体免疫力的作用,能有效的***、肝硬化、肝腹水、类风湿、颈椎病、腰椎病、以及病毒性肺炎并发的咽炎、咳嗽、哮喘、肺心病、心脑血管病,纯药食同源制剂、无毒毒作用;我家祖辈采用槐花400g、蛹虫草300g、平卧菊三七300g、沙棘300g、余甘子200g、小蓟100g制成制剂治疗以上病症疗效显著,视为祖传秘方传至本人,本人将此方进行过数百次的处方重组,组合后的制剂的疗效都弱于原配方的疗效,为此确定祖辈配比之方的最佳方;方中每味中药都是药食同源,且功能各有不同,其中槐花的功效与作用:1、降低血压、预防中风,槐花中含有大量的芦丁,这种特质是增加毛细血管抵抗力的重要物质,可以改善毛细血管的功能,增加血管壁的弹性,大大降低人们出现脑血管破裂的机率,从而起到预防中风以及高血压的作用;2、清肝泻火,由于槐花入肝经,所以对于肝火旺盛,头痛目赤,喉咙肿痛,失音,痈疽疮疡等也有不错的治疗效果;3、凉血止血,槐花味苦、性微寒,在中医理论中归肝、大肠经,是一种药用价值很高的物质,它具有凉血止血的特殊功效,在临床上多用于出血和血热型的病症的配合治疗,对于便血、尿血以及痔血等疾病都有不错的疗效;4、抗炎灭菌,槐花中所含有的芸香甙和槐花二醇以及多种糖类,可以迅速杀死人体血液中的有害物质,并且阻止它们在人体中的流通,预防各种炎症的发生,另外在皮肤上涂上槐花的汁液能很好地抵抗真菌;沙棘:具有健脾消食、止咳化痰、活血祛瘀的功效,临床主要用于治疗身体出现的脾胃功能虚弱以及咳嗽、咳痰等临床表现症状,另外,经常食用沙棘,对肝脏有良好的保护和促进肝功能代谢作用,减少肝功能造成损伤,对于改善肝功能、抗肝硬化、抗脂肪肝都有良好的作用,沙棘含有丰富的维生素以及多种纤维素,对于癌变组织有明显的抗癌活性和抗癌作用,对体内的癌细胞有一定抑制和杀伤作用,沙棘对免疫力低下以及皮肤美容、神经衰弱,都有良好的调理和治疗作用,有明显对抗的心肌缺血和改善动脉痉挛的作用,对实验性动物具有对抗心肌缺血损伤,缩小心肌梗塞面积的作用。能明显地抑制心室纤维化、沙棘黄酮通过刺激前列环素和内皮舒张因子的生成而产生动脉舒张作用,共同保持动脉和静脉血管的张力,使受损部位和周围组织血流增加,改善血管壁的通透性,其根本功效体现在:清洗血液、祛除血毒、净化血液、通畅血管、肠胃改善、睡眠踏实、健康长寿;蛹虫草:又名北冬虫夏草,蛹草,北虫草,蛹草菌等,据中医专家研究指出,蛹虫草所含的虫草素高,抗衰老,抗超氧化物歧化酶(SOD)比芦荟高2倍。赵学敏在《本草纲目拾遗》中把虫草类的药用归之为“能治百虚百损”。李时珍在《本草纲目》中指出,蝉花能主治“小儿天吊惊痛,夜啼,心悸”。其中蝉花包括蝉草和蛹草等多种寄生于蝉体上的虫草。多年来的研究表明,蛹虫草内含有虫草素、虫草酸、多糖、腺苷等多种有效成分,可降血脂,防止动脉硬化,保护心、脑组织,镇静催眠,增强巨噬细胞的活性,抗炎、抗癌、抗菌、抗衰老等;余甘子:性凉,能清热、凉血、润肺,可改善中暑、风热、慢性咽炎等不适,并可治疗消渴、高血压、高脂血症、糖尿病、消化不良等;平卧菊三七:主要食用嫩茎叶,具有清热解毒、止血止咳、减少血管紫癜、提高人体免疫力和抗病毒能力;泻火、凉血、消炎、生津等功效,对于肿病有一定的疗效;经安全性评价研究,平卧菊三七是一种无毒级的优质特种保健蔬菜,根茎是中成药上佳的原材料。其作菜食用或药用,可以补钙、抗病毒、抗感冒,提高免疫力等功效,外用对带状疱疹、各种皮炎、烫伤、烧伤及无名肿痛均有良好的疗效,还可以止血、止痛、止痒及护肤保湿抗衰老;据《中国中草药汇编》下册记载:其疗效为味甘淡,性平,通经活络,消炎止咳,散瘀消肿,活血生肌,主要用于治疗跌打损伤、风湿关节痛和痛风;经营养和化学分析,该植物富含有机钙,是中老年人最佳的补钙绿色食品;平卧菊三七含有丰富的有机酸成分及黄酮类化合物,有机酸成分中新氯原酸具有很好的抗病毒和增强人体免疫力功效,对抑制乙型肝炎病毒有显著的作用,还具有抗艾滋病病毒以及流感病毒的作用;小蓟:用于吐血、蛆血、尿血、便血、崩漏、外伤出血、痈肿疮毒、湿疹、黄疽等,用于肝炎、肾炎、高血压病、支气管扩张咯血、消化道出血、痔疮出血、功能性子宫出血、产后宫缩不全、细菌性痢疾、皮肤溃疡、外伤化脓性感染等;以上每味中药,人们已当食品使用上千年,纯药食同源、无毒副作用、剂量可根据需求进行加减,用于那些重型病毒感染性肺炎的并发症治疗时可加入广东刘寄奴(四季菜)、灵芝、白芷为辅料,提升患者的免疫功能,达到快速康复的目的,制剂可开发成茶饮(固体饮料)、保健食品、中成药,同时也可以某种优质酒为基酒、加入槐花蛹虫草制剂制成药食同源保健酒。
制备方法:制取时选用槐花4kg、蛹虫草3kg、平卧菊三七3kg、沙棘3Kg、余甘子2Kg、小蓟1kg(此配方是本人经过数百次试用得出的最佳配比、改变配方比例,疗效将会倍减)进行多次浓缩,加入适量辅料,制成16kg的浓缩粉,然后用瓶装备用。
用量与用法:每日2一3次、每次3.3克,用温开水冲服。
实施例:<1>、谭XX,女,48岁,因有颈椎病、腰椎病类风湿久治不愈,经常全身以及关节痛疼难忍,在医院治疗了一年无明显好转,于2008年8月9日来我处进行治疗,本人给她开了按以上制备方法制成的槐花蛹虫草制剂<停服其它中西药>,每日二次、每次3.3克、服用15天后,明显好转,连服4个月后停服,通过医院复查颈椎病、腰椎病、类风湿均已康复,身体一切正常,随仿三年,颈椎病、腰椎病未复化,类风湿因子均为阴性。
<2>、姜×,男,55岁,因病毒感染引发肺炎久治不愈、转为哮喘、肺心病,在医院使用各种西药达2年之久、病症无明显改善、停药就感觉身体异常,生活质量很不理想、随时处于病危状态,全辈呼吸机维持生命、过着生不如死的日子,于2011年4月8日来我处服用按此制备方法制备的槐花蛹虫草制剂,停服其它药物,每日二次、每次6.6g,一个月后病情得到控制,可正常从事一般劳动,第二个月后用量减半、连服了五个月,一切正常,停药后随仿二年未复发,至今身体健康。
<3>、徐××,男,60岁,2002年11月1日发现乙肝大三阳,肝功能轻度异常,在大小医院久治未愈,2009年1月1日,因感冒出现咳嗽、几天后咳咳加重、伴有气喘无力,心动过速,去大医院检查:诊断为乙肝所至的肝硬化、肝腹水,同时伴有咳嗽、哮喘、肺心病,服用多种中西药无明显好转、整天感觉全身不适,在医院治疗几个月无好转,于2009年7月8日到我处服用、按此制备方法制备的槐花蛹虫草制剂,每次6.6g、每日3次(停服其药物),使用20天后、感觉明显好转,继续使用了9个月去医院复查,肝硬化、肝腹水已康复,乙肝大三阳转小三阳、乙肝病毒转阴,哮喘、肺心病已控制,无任何不适之感、达到了临床停药标准,停药后很少出现咳嗽、至今未出现病情反复,能正常劳动,身体健康。
Claims (1)
1.槐花蛹虫草制剂其特症是由:槐花400g、蛹虫草300g、平卧菊三七300g、沙棘300g、余甘子200g、小蓟100g制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010404779.9A CN111437301A (zh) | 2020-05-03 | 2020-05-03 | 槐花蛹虫草制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010404779.9A CN111437301A (zh) | 2020-05-03 | 2020-05-03 | 槐花蛹虫草制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111437301A true CN111437301A (zh) | 2020-07-24 |
Family
ID=71657534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010404779.9A Pending CN111437301A (zh) | 2020-05-03 | 2020-05-03 | 槐花蛹虫草制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111437301A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113244275A (zh) * | 2021-07-02 | 2021-08-13 | 上海市公共卫生临床中心 | 一种蛹虫草药物组合物在制备用于预防和/或治疗新冠及抗呼吸道病毒制剂中的应用 |
-
2020
- 2020-05-03 CN CN202010404779.9A patent/CN111437301A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113244275A (zh) * | 2021-07-02 | 2021-08-13 | 上海市公共卫生临床中心 | 一种蛹虫草药物组合物在制备用于预防和/或治疗新冠及抗呼吸道病毒制剂中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105995720A (zh) | 一种酵素莱阳梨膏及其制备方法和应用 | |
CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
CN113041293A (zh) | 一种用于治疗动脉粥样硬化的中药组合物 | |
CN103720903A (zh) | 一种抗炎清肺护肝茶及其制作方法 | |
CN102600417B (zh) | 一种治疗牛羊瘤胃鼓气的中药组合物 | |
CN102552779A (zh) | 具有净化人体血液作用的保健中药组合物及其保健制品 | |
CN111437301A (zh) | 槐花蛹虫草制剂 | |
CN104274649B (zh) | 一种用于口腔溃疡的药物 | |
CN106038743A (zh) | 一种降血压冲剂、制备方法及其应用 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN102579872B (zh) | 一种具有减肥功效的药物组合物 | |
CN102698185B (zh) | 一种治疗高血脂症的藏药及其制备方法 | |
CN101669995A (zh) | 一种用于心脑血管疾病治疗和保健的组合物及其制备方法 | |
CN105031595A (zh) | 一种治疗钱币状湿疹的中药片剂及其制备方法 | |
CN104524461A (zh) | 一种治疗心肌炎的药物组合物及其应用 | |
CN115252732B (zh) | 一种清肺止咳的中药组合物及其应用 | |
CN108713711A (zh) | 中药保健组合物、固体保健饮料及其制备方法和应用 | |
CN107213283A (zh) | 一种抗疲劳、平衡阴阳的食药两用中药组合物及其制备方法 | |
CN101837062B (zh) | 一种降脂***片 | |
CN105125886A (zh) | 一种用于预防和治疗糖尿病及其并发症的中药组合物 | |
CN113144079A (zh) | 一种用于防治流行性感冒的中药制剂及其制备方法 | |
CN104998189A (zh) | 一种治疗风热乘脾型小儿口疮的中药散剂及其制备方法 | |
CN104825883A (zh) | 一种治疗鼻炎的中药方剂 | |
CN104758757A (zh) | 一种治疗足癣的中药组合物及其制备方法 | |
CN108704109A (zh) | 一种治疗痤疮的中药组合物及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200724 |
|
WD01 | Invention patent application deemed withdrawn after publication |